Investor Presentation First Nine Months of 2023
62
Investor presentation
First nine months of 2023
Novo NordiskⓇ
Across the STEP 1, 3, and 4 trials, a weight loss of 16.9% to 18.2%
was reported for people treated with semaglutide 2.4 mg
STEP 1
Weight
management
STEP 3
Weight mgmt.
STEP 4
Sustained weight management
with IBT
STEP 5
Weight loss over 2
years
STEP 2
Weight mgmt.
with T2D
STEP 8
Head-to-head trial versus
liraglutide 3.0 mg
After 68 weeks
After 20 weeks
105.8
107.2
96.1
106.0
104.5
Baseline body
weight, kg
105.3
99.8
Sema
Placebo
Sema
IBT
Sema
Placebo
9
+ IBT
Sema Placebo Sema
6.5
Placebo
Sema
Placebo
Sema
Lira 3.0 mg Placebo
Change from baseline
in BW (%)
-9
-2.4
-5.0
-5.2
-8.8
-18
*
-16.9
-17.6*
-18.2*
-16.7
-0.6
-3.1
-6.6
* P-value <0.0001, based on the trial product estimand (secondary statistical approach): treatment effect if all people adhered to treatment and did not initiate other anti-obesity therapies
IBT: Intensive behavioural therapy; Sema: Semaglutide; Lira: Liraglutide; BW: Body weight; T2D: Type 2 diabetes; Mgmt.: Management
-10.6
*
-17.1
*
-1.8View entire presentation